creatine has been researched along with Electron Transport Chain Deficiencies, Mitochondrial in 23 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Recent investigations have suggested creatine (Cr) as an additional biomarker of mitochondrial diseases." | 7.79 | Role of creatine as biomarker of mitochondrial diseases. ( Arias, A; Briones, P; García-Villoria, J; Pajares, S; Ribes, A, 2013) |
| "Creatine is a molecule that is produced both endogenously, and acquired exogenously through diet, and is an extremely important molecule that participates in buffering intracellular energy stores." | 6.44 | Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseases. ( Adhihetty, PJ; Beal, MF, 2008) |
| "Semiquantitative analysis of NAA relative to creatine-containing compounds (Cr) and choline (Cho) was carried out from proton spectra obtained by means of chemical shift (CS) imaging and single-voxel (SV) methods in 25 patients with severe traumatic brain injuries (TBIs) (Glasgow Coma Scale scores < or = 8) using a 1." | 5.13 | Assessment of mitochondrial impairment in traumatic brain injury using high-resolution proton magnetic resonance spectroscopy. ( Aygok, GA; Bullock, RM; Fatouros, PP; Marmarou, A; Portella, G; Signoretti, S, 2008) |
| "Recent investigations have suggested creatine (Cr) as an additional biomarker of mitochondrial diseases." | 3.79 | Role of creatine as biomarker of mitochondrial diseases. ( Arias, A; Briones, P; García-Villoria, J; Pajares, S; Ribes, A, 2013) |
| "Studies using the mdx model of Duchenne muscular dystrophy have found evidence of enhanced mitochondrial function, reduced intra-cellular calcium and improved performance with CrM supplementation." | 2.44 | Clinical use of creatine in neuromuscular and neurometabolic disorders. ( Tarnopolsky, MA, 2007) |
| "Creatine is a molecule that is produced both endogenously, and acquired exogenously through diet, and is an extremely important molecule that participates in buffering intracellular energy stores." | 2.44 | Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseases. ( Adhihetty, PJ; Beal, MF, 2008) |
| "Patients with mitochondrial disorders offer a unique window through which we can begin to understand the association between psychiatric symptoms and mitochondrial dysfunction in vivo." | 1.38 | Psychiatric symptoms correlate with metabolic indices in the hippocampus and cingulate in patients with mitochondrial disorders. ( Anglin, RE; Mazurek, MF; Noseworthy, MD; Rosebush, PI; Tarnopolsky, M, 2012) |
| "Recently, the clinical spectrum of dominant optic atrophy has been extended to frequent syndromic forms, exhibiting various degrees of neurological and muscle impairments frequently found in mitochondrial diseases." | 1.38 | The human OPA1delTTAG mutation induces premature age-related systemic neurodegeneration in mouse. ( Angebault, C; Bielicki, G; Boddaert, N; Brabet, P; Cazevieille, C; Chaix, B; Delettre, C; Gueguen, N; Hamel, CP; Lenaers, G; Mausset-Bonnefont, AL; Puel, JL; Renou, JP; Reynier, P; Rigau, V; Sarzi, E; Seveno, M; Wang, J, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (39.13) | 29.6817 |
| 2010's | 14 (60.87) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ostojic, SM | 1 |
| Liu, J | 1 |
| Wang, LN | 1 |
| Reid, CA | 1 |
| Mullen, S | 1 |
| Kim, TH | 1 |
| Petrou, S | 1 |
| Lunsing, RJ | 1 |
| Strating, K | 1 |
| de Koning, TJ | 1 |
| Sijens, PE | 1 |
| DeBrosse, C | 1 |
| Nanga, RPR | 1 |
| Wilson, N | 1 |
| D'Aquilla, K | 1 |
| Elliott, M | 1 |
| Hariharan, H | 1 |
| Yan, F | 1 |
| Wade, K | 1 |
| Nguyen, S | 1 |
| Worsley, D | 1 |
| Parris-Skeete, C | 1 |
| McCormick, E | 1 |
| Xiao, R | 1 |
| Cunningham, ZZ | 1 |
| Fishbein, L | 1 |
| Nathanson, KL | 1 |
| Lynch, DR | 1 |
| Stallings, VA | 1 |
| Yudkoff, M | 1 |
| Falk, MJ | 1 |
| Reddy, R | 1 |
| McCormack, SE | 1 |
| Tarnopolsky, MA | 2 |
| Adhihetty, PJ | 1 |
| Beal, MF | 3 |
| Orsucci, D | 1 |
| Filosto, M | 1 |
| Siciliano, G | 1 |
| Mancuso, M | 1 |
| Shaham, O | 1 |
| Slate, NG | 1 |
| Goldberger, O | 1 |
| Xu, Q | 1 |
| Ramanathan, A | 1 |
| Souza, AL | 1 |
| Clish, CB | 1 |
| Sims, KB | 1 |
| Mootha, VK | 1 |
| Hathaway, SC | 1 |
| Friez, M | 1 |
| Limbo, K | 1 |
| Parker, C | 1 |
| Salomons, GS | 1 |
| Vockley, J | 1 |
| Wood, T | 1 |
| Abdul-Rahman, OA | 1 |
| Naia, L | 1 |
| Ribeiro, MJ | 1 |
| Rego, AC | 1 |
| Pfeffer, G | 1 |
| Majamaa, K | 2 |
| Turnbull, DM | 1 |
| Thorburn, D | 2 |
| Chinnery, PF | 1 |
| Stride, N | 1 |
| Larsen, S | 1 |
| Hey-Mogensen, M | 1 |
| Sander, K | 1 |
| Lund, JT | 1 |
| Gustafsson, F | 1 |
| Køber, L | 1 |
| Dela, F | 1 |
| Anglin, RE | 1 |
| Rosebush, PI | 1 |
| Noseworthy, MD | 1 |
| Tarnopolsky, M | 1 |
| Mazurek, MF | 1 |
| Sarzi, E | 1 |
| Angebault, C | 1 |
| Seveno, M | 1 |
| Gueguen, N | 1 |
| Chaix, B | 1 |
| Bielicki, G | 1 |
| Boddaert, N | 1 |
| Mausset-Bonnefont, AL | 1 |
| Cazevieille, C | 1 |
| Rigau, V | 1 |
| Renou, JP | 1 |
| Wang, J | 1 |
| Delettre, C | 1 |
| Brabet, P | 1 |
| Puel, JL | 1 |
| Hamel, CP | 1 |
| Reynier, P | 1 |
| Lenaers, G | 1 |
| Pajares, S | 1 |
| Arias, A | 1 |
| García-Villoria, J | 1 |
| Briones, P | 1 |
| Ribes, A | 1 |
| Kerr, DS | 1 |
| Chinnery, P | 1 |
| Turnbull, D | 1 |
| Marmarou, A | 2 |
| Signoretti, S | 2 |
| Fatouros, P | 1 |
| Aygok, GA | 2 |
| Bullock, R | 1 |
| Rodriguez, MC | 1 |
| MacDonald, JR | 1 |
| Mahoney, DJ | 1 |
| Parise, G | 1 |
| Fatouros, PP | 1 |
| Portella, G | 1 |
| Bullock, RM | 1 |
| Bizzi, A | 1 |
| Castelli, G | 1 |
| Bugiani, M | 1 |
| Barker, PB | 1 |
| Herskovits, EH | 1 |
| Danesi, U | 1 |
| Erbetta, A | 1 |
| Moroni, I | 1 |
| Farina, L | 1 |
| Uziel, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Utility of pGz in Primary Mitochondrial Disorders[NCT05569122] | Phase 1 | 90 participants (Anticipated) | Interventional | 2023-03-22 | Recruiting | ||
| Development and Validation of a Myopathy Rating Scale in Mitochondrial Disease[NCT05250375] | 20 participants (Anticipated) | Observational [Patient Registry] | 2017-03-24 | Recruiting | |||
| A Phase 2a Study of NAD+ Precursor Supplementation in Friedreich's Ataxia[NCT04817111] | Phase 2 | 7 participants (Actual) | Interventional | 2021-05-17 | Completed | ||
| A Phase II, Monocenter, Single Arm Study To Assess The Safety and Efficacy Of Combination Deoxycytidine and Deoxythymidine For Mitochondrial Depletion Disorders[NCT04802707] | Phase 2 | 50 participants (Anticipated) | Interventional | 2021-10-18 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Measure the within-participant change in PCr/ATP ratio before and after treatment with MIB-626. (NCT04817111)
Timeframe: Change from baseline to 14 days.
| Intervention | PCr to ATP ratio (Median) |
|---|---|
| Open Label - MIB-626 | -0.445 |
Measure the concentration of NAD+ in whole blood before and after treatment with MIB-626. (NCT04817111)
Timeframe: Change from baseline to 14 days.
| Intervention | micro-molar (Median) |
|---|---|
| Open Label - MIB-626 | 49.9 |
Assess within-participant changes in grip strength (via hand grip dynamometry) before and after treatment with MIB-626. (NCT04817111)
Timeframe: Change from baseline to 14 days.
| Intervention | kg (Median) |
|---|---|
| Open Label - MIB-626 | -0.65 |
Safety will be monitored through collection of laboratory assessments (CBC, complete metabolic profile, lipid profile, HbA1c), vital signs (heart rate, blood pressure), and ECG, all of which will be reviewed for clinically relevant abnormalities, and standardized assessment of symptoms. We report the proportion of individuals who had at least one treatment-emergent adverse event of Grade 1 or higher. (NCT04817111)
Timeframe: 14 Days
| Intervention | Participants (Count of Participants) |
|---|---|
| Open Label - MIB-626 | 4 |
9 reviews available for creatine and Electron Transport Chain Deficiencies, Mitochondrial
| Article | Year |
|---|---|
Mitochondrial enhancement for neurodegenerative movement disorders: a systematic review of trials involving creatine, coenzyme Q10, idebenone and mitoquinone.
Topics: Animals; Creatine; Dose-Response Relationship, Drug; Humans; Mitochondria; Mitochondrial Diseases; N | 2014 |
Epilepsy, energy deficiency and new therapeutic approaches including diet.
Topics: Adenosine Triphosphatases; Adenosine Triphosphate; Astrocytes; Creatine; Diet, Ketogenic; Energy Int | 2014 |
Clinical use of creatine in neuromuscular and neurometabolic disorders.
Topics: Animals; Body Composition; Charcot-Marie-Tooth Disease; Creatine; Disease Models, Animal; Glycogen S | 2007 |
Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseases.
Topics: Adenosine Triphosphate; Animals; Creatine; Dietary Supplements; Energy Metabolism; Humans; Mitochond | 2008 |
Electron transfer mediators and other metabolites and cofactors in the treatment of mitochondrial dysfunction.
Topics: Acidosis, Lactic; Animals; Antioxidants; Carnitine; Creatine; Dietary Supplements; Electron Transpor | 2009 |
Mitochondrial and metabolic-based protective strategies in Huntington's disease: the case of creatine and coenzyme Q.
Topics: Animals; Creatine; Disease Models, Animal; Humans; Huntington Disease; Metabolic Diseases; Mitochond | 2011 |
Treatment for mitochondrial disorders.
Topics: Creatine; Dichloroacetic Acid; Humans; Mitochondrial Diseases; Randomized Controlled Trials as Topic | 2012 |
Review of clinical trials for mitochondrial disorders: 1997-2012.
Topics: Antioxidants; Arginine; Clinical Trials as Topic; Creatine; Exercise Therapy; Humans; Mitochondrial | 2013 |
Treatment for mitochondrial disorders.
Topics: Creatine; Dichloroacetic Acid; Humans; Mitochondrial Diseases; Sarcosine; Ubiquinone | 2006 |
3 trials available for creatine and Electron Transport Chain Deficiencies, Mitochondrial
| Article | Year |
|---|---|
Mitochondrial injury measured by proton magnetic resonance spectroscopy in severe head trauma patients.
Topics: Adult; Aspartic Acid; Biomarkers; Brain; Brain Ischemia; Choline; Craniocerebral Trauma; Creatine; F | 2005 |
Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adolescent; Adult; Analysis of Variance; Antioxidants; Body Composition | 2007 |
Assessment of mitochondrial impairment in traumatic brain injury using high-resolution proton magnetic resonance spectroscopy.
Topics: Adolescent; Adult; Aspartic Acid; Brain Injuries; Choline; Creatine; Female; Follow-Up Studies; Huma | 2008 |
11 other studies available for creatine and Electron Transport Chain Deficiencies, Mitochondrial
| Article | Year |
|---|---|
Plasma creatine as a marker of mitochondrial dysfunction.
Topics: Adenosine Triphosphate; Biomarkers; Creatine; Creatine Kinase, Mitochondrial Form; Electron Transpor | 2018 |
Diagnostic value of MRS-quantified brain tissue lactate level in identifying children with mitochondrial disorders.
Topics: Adolescent; Biomarkers; Brain; Child; Child, Preschool; Creatine; Female; Humans; Infant; Infant, Ne | 2017 |
Muscle oxidative phosphorylation quantitation using creatine chemical exchange saturation transfer (CrCEST) MRI in mitochondrial disorders.
Topics: Adult; Creatine; Exercise Test; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Mitoc | 2016 |
Muscle oxidative phosphorylation quantitation using creatine chemical exchange saturation transfer (CrCEST) MRI in mitochondrial disorders.
Topics: Adult; Creatine; Exercise Test; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Mitoc | 2016 |
Muscle oxidative phosphorylation quantitation using creatine chemical exchange saturation transfer (CrCEST) MRI in mitochondrial disorders.
Topics: Adult; Creatine; Exercise Test; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Mitoc | 2016 |
Muscle oxidative phosphorylation quantitation using creatine chemical exchange saturation transfer (CrCEST) MRI in mitochondrial disorders.
Topics: Adult; Creatine; Exercise Test; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Mitoc | 2016 |
Muscle oxidative phosphorylation quantitation using creatine chemical exchange saturation transfer (CrCEST) MRI in mitochondrial disorders.
Topics: Adult; Creatine; Exercise Test; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Mitoc | 2016 |
Muscle oxidative phosphorylation quantitation using creatine chemical exchange saturation transfer (CrCEST) MRI in mitochondrial disorders.
Topics: Adult; Creatine; Exercise Test; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Mitoc | 2016 |
Muscle oxidative phosphorylation quantitation using creatine chemical exchange saturation transfer (CrCEST) MRI in mitochondrial disorders.
Topics: Adult; Creatine; Exercise Test; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Mitoc | 2016 |
Muscle oxidative phosphorylation quantitation using creatine chemical exchange saturation transfer (CrCEST) MRI in mitochondrial disorders.
Topics: Adult; Creatine; Exercise Test; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Mitoc | 2016 |
Muscle oxidative phosphorylation quantitation using creatine chemical exchange saturation transfer (CrCEST) MRI in mitochondrial disorders.
Topics: Adult; Creatine; Exercise Test; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Mitoc | 2016 |
A plasma signature of human mitochondrial disease revealed through metabolic profiling of spent media from cultured muscle cells.
Topics: Adult; Animals; Biomarkers; Cell Line; Creatine; Culture Media; Electron Transport; Female; Humans; | 2010 |
Therapeutic approaches to mitochondrial dysfunction in Parkinson's disease.
Topics: Animals; Clinical Trials, Phase III as Topic; Creatine; Heat-Shock Proteins; Histocompatibility Anti | 2009 |
X-linked creatine transporter deficiency presenting as a mitochondrial disorder.
Topics: Adolescent; Biomarkers; Creatine; Diagnosis, Differential; Genetic Diseases, X-Linked; Humans; Inclu | 2010 |
Decreased mitochondrial oxidative phosphorylation capacity in the human heart with left ventricular systolic dysfunction.
Topics: Aged; Biopsy; Carnitine; Creatine; Creatine Kinase, Mitochondrial Form; Energy Metabolism; Fatty Aci | 2013 |
Psychiatric symptoms correlate with metabolic indices in the hippocampus and cingulate in patients with mitochondrial disorders.
Topics: Adult; Aged; Anxiety; Aspartic Acid; Case-Control Studies; Caudate Nucleus; Creatine; Female; Glutam | 2012 |
The human OPA1delTTAG mutation induces premature age-related systemic neurodegeneration in mouse.
Topics: Acoustic Stimulation; Age Factors; Aging, Premature; Animals; Aspartic Acid; Chi-Square Distribution | 2012 |
Role of creatine as biomarker of mitochondrial diseases.
Topics: Adolescent; Adult; Biomarkers; Child; Child, Preschool; Creatine; Humans; Infant; Infant, Newborn; L | 2013 |
Classification of childhood white matter disorders using proton MR spectroscopic imaging.
Topics: Adrenoleukodystrophy; Adult; Alexander Disease; Aspartic Acid; Brain; Child; Child, Preschool; Choli | 2008 |